A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
By Zachary A. Knight, B. González, M. Feldman, E. Zunder, David D. Goldenberg, O. Williams, R. Loewith, D. Stokoe, A. Balla, B. Tóth and 4 more. 2006
1,146 citations recorded by the source corpus.
Subfields: Molecular Biology
View Paper: https://www.semanticscholar.org/paper/0b3b4465396deda32b6c74030afe241c59876063
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- David M. Sabatini
- Lewis C. Cantley
- K. Guan
- Michael N. Hall
- T. Balla
- M. Laplante
- J. Engelman
- D. Klionsky
Citations in the corpus
- Viral Reorganization of the Secretory Pathway Generates Distinct Organelles for RNA Replication (2010, positive): “PI4KIIIb Activity Regulates Viral RNA Synthesis To determine whether PI4KIIIb kinase activity was required for enteroviral RNA replication, we measured the effect of the small molecule PIK93, which selectively inhibits PI4KIIIb (Knight et al., 2006), and found that enteroviral RNA replication was si”
- mTOR and cancer: insights into a complex relationship (2006, background): “67 ), which is a molecule that inhibits the kinase activity of both mTOR and PI3K p110α (the isoform of the PI3K catalytic subunit that activates Akt in response to insuli”
- Comparing antibody and small-molecule therapies for cancer (2006, methodology): “have recently used a systematic approach for parallel evaluation using a chemically diverse panel of small-molecule inhibitors that target the PI3K famil”
- Targeting phosphoinositide 3-kinase: moving towards therapy. (2008, background): “023 PIK-124 Warner Lambert Pan-PI3K inhibitor [221] WO2004056820 WO2004052373 1.”
- PI3K pathway alterations in cancer: variations on a theme (2008, positive): “Other PI3K inhibitors occupy the ATP-binding site and extend into an affinity pocket where it makes hydrophobic interactions that increase the affinity of the compound for the enzyme (Knight et al., 2006).”
- A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. (2006, positive): “In contrast to PIK-90 and PIK-85, PI-103 does show more potent inhibition of p110b (Knight et al., 2006).”